

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *						Issuer Name and Ticker or Trading Symbol									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
Maveron General Partner III LLC						TRUPANION INC. [TRUP]												
(Last) (First) (Middle)				3.]	3. Date of Earliest Transaction (MM/DD/YYYY)								Director X 10% Owner Officer (give title below) Other (specify below)					
411 FIRST AVENUE SOUTH, SUITE 600						5/5/2017												
					4.]	4. If Amendment, Date Original Filed (MM/DD/YYYY)							Y) 6. Individua	6. Individual or Joint/Group Filing (Check Applicable Line)				
SEATTLE, WA 98104 (City) (State) (Zip)														Form filed by One Reporting Person X Form filed by More than One Reporting Person				
			Table	I - No	n-Dei	ivat	ive Sec	uritie	s Ac	quire	ed, Dis	posed o	f, or	Beneficially Ow	ned			
1.Title of Security (Instr. 3)				2. Trans. Da		te 2A. Deemed Execution Date, if any		3. Trans. Code (Instr. 8)			or Dispo	ities Acqu osed of (D) 4 and 5)	ired (A	5. Amount of Sect Following Reporte (Instr. 3 and 4)	Amount of Securities Beneficially Owned bllowing Reported Transaction(s) nstr. 3 and 4)			7. Nature of Indirect Beneficial Ownership
								Со	ode	V	Amount	(A) or (D)	Prio	e			Direct (D) or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock				5/5/2	017			J	<u>(1)</u>		847787	D	\$0		3860472		I	See Footnote
Common Stock				5/5/2	017			J	<u>(3)</u>		8478	A	\$0		8478		D	
Common Stock				5/5/2	017			J	<u>(4)</u>		116243	D	\$0		529323		I	See Footnote (5)
Common Stock				5/5/2	017			J	<u>(6)</u>		35970	D	\$0		163791		I	See Footnote
Common Stock				5/5/2	017			J	(8)		360	A	\$0		8838		D	
Common Stock				5/5/2	017			J	<u>(9)</u>		2755	D	\$0		6083		D	
Common Stock				5/5/2	017			JС	<u>10)</u>		622	A	\$0		1655		I	See Footnote (11)
	Tabl	e II - Deri	ivative	Secui	rities]	Bene	ficially	Own	ned (e.g. ,	, puts, o	calls, wa	arrar	ts, options, con	vertible sec	curities)		
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	Date			. Trans. Instr. 8)	Code	Acquired Disposed	ve Securities d (A) or					Secur Deriv	e and Amount of ties Underlying tive Security 3 and 4)	nderlying Derivative der Security 4) (Instr. 5) Be Ov	9. Number of derivative Securities Beneficially Owned Following	Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Cod		v	(A)	((D)	Date Exerc	cisable E	Expiration Date	Title	Amount or Number Shares	nt or Number of Reported			

Explanation of Responses:

- (1) Maveron Equity Partners III, L.P. ("Maveron Equity") made pro rata distributions for no consideration of 847,787 shares of common stock of the issuer to its partners on May 5, 2017.
- (2) Shares are owned directly by Maveron Equity. Maveron General Partner III LLC ("Maveron GP"), which is the general partner of Maveron Equity, has sole voting and investment power over the securities held by Maveron Equity. Maveron GP disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein. In addition, Dan Levitan, who is a Director of the issuer, and certain other individuals are managing members of Maveron GP and may be deemed to share voting and investment power over the shares held of record by Maveron Equity. Each of such individuals disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. The inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- (3) Shares acquired by Maveron GP in connection with the distribution of such shares to the partners of Maveron Equity.
- (4) MEP Associates III, L.P. ("Maveron Associates") made pro rata distributions for no consideration of 116,243 shares of common stock of the issuer to its partners on May 5, 2017.
- (5) Shares are owned directly by Maveron Associates. Maveron GP, which is the general partner of Maveron Associates, has sole voting and investment power over the securities held by Maveron Associates. Maveron GP disclaims beneficial ownership over such securities except to the extent of its pecuniary

interest therein. In addition, Dan Levitan, who is a Director of the issuer, and certain other individuals are managing members of Maveron GP and may be deemed to share voting and investment power over the shares held of record by Maveron Associates. Each of such individuals disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. The inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

- (6) Maveron III Entrepreneurs Fund, L.P. ("Maveron Entrepreneurs") made pro rata distributions for no consideration of 35,970 shares of common stock of the issuer to its partners on May 5, 2017.
- (7) Shares are owned directly by Maveron Entrepreneurs. Maveron GP, which is the general partner of Maveron Entrepreneurs, has sole voting and investment power over the securities held by Maveron Entrepreneurs. Maveron GP disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein. In addition, Dan Levitan, who is a Director of the issuer, and certain other individuals are managing members of Maveron GP and may be deemed to share voting and investment power over the shares held of record by Maveron Entrepreneurs. Each of such individuals disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. The inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- (8) Shares acquired by Maveron GP in connection with the distribution of such shares to the partners of Maveron Entrepreneurs.
- (9) Mayeron GP made pro rata distributions for no consideration of 2,755 shares of common stock of the issuer to its members on May 5, 2017.
- (10) Shares acquired by Maveron LLC in connection with the distribution of such shares to the partners of Maveron Equity and Maveron Entrepreneurs.
- (11) Shares are owned directly by Maveron LLC. Maveron LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein. In addition, Dan Levitan, who is a Director of the issuer, and certain other individuals are managing members of Maveron LLC and may be deemed to share voting and investment power over the shares held of record by Maveron LLC. Each of such individuals disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. The inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Remarks:

Each reporting person disclaims the existence of a "group" and disclaims beneficial ownership of any securities except to the extent of such reporting persons' pecuniary interest in such securities.

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Maveron General Partner III LLC						
411 FIRST AVENUE SOUTH, SUITE 600		X				
SEATTLE, WA 98104						
Maveron Equity Partners III, L.P.						
411 FIRST AVENUE SOUTH, SUITE 600		X				
SEATTLE, WA 98104						
Maveron III Entrepreneurs Fund, L.P.						
411 FIRST AVENUE SOUTH, SUITE 600		X				
SEATTLE, WA 98104						
MEP Associates III, L.P.						
411 FIRST AVENUE SOUTH, SUITE 600		X				
SEATTLE, WA 98104						
Maveron LLC						
411 FIRST AVENUE SOUTH, SUITE 600		X				
SEATTLE, WA 98104						

Signatures

/s/ Pete McCormick, as managing member of Maveron General Partner III, LLC					
** Signature of Reporting Person					
/s/ Pete McCormick, as managing member of the GP of Maveron Equity Partners III, L.P.					
** Signature of Reporting Person	Date				
/s/ Pete McCormick, as managing member of the GP of Maveron III Entrepreneurs Fund LP					
** Signature of Reporting Person	Date				
/s/ Pete McCormick, as managing member of the GP of MEP Associates III, L.P.					
** Signature of Reporting Person	Date				
/s/ Pete McCormick, as Attorney-in-Fact for Maveron LLC					
** Signature of Reporting Person					

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.